ClinicalTrials.gg
RecruitingNCT07070791Updated Nov 17, 2026

Combined Upper Extremity Resistance and Aerobic Exercise Training in Patients With Breast Cancer

An interventional study of Upper Extremity Aerobic Exercise Training and Upper Extremity Progressive Resistance Exercise Training in Breast Cancer, Upper Extremity and Resistance Exercise, sponsored by Hacettepe University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hacettepe University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Breast Neoplasms by Hacettepe University — 4 open to participants now, 4 under way, none of them phase 3. Breast Neoplasms · Hacettepe University.

Planned enrollment
7th of 10
40 · median 45
Started
2025
with 3 others
No phase
10 of 16
4 open now
Registered
13th of 16
by date

Among the 16 studies in Breast Neoplasms by Hacettepe University, this one is the 7th largest by planned enrollment of the 10 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 with no phase, and was the 13th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 16 studies in Breast Neoplasms by Hacettepe University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 80 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Breast Neoplasms by Hacettepe University, or all of them as a file.
02

Study summary

According to updated data from the International Agency for Research on Cancer (IARC) for 2022, breast cancer in women is responsible for one in four cancer cases and one in six cancer deaths worldwide and is the second leading cause of global cancer incidence, accounting for 11.6% of all cancer cases, and the fourth leading cause of cancer deaths worldwide, accounting for 6.9% of all cancer deaths. During or after breast cancer treatments, there is exposure to a variety of direct (local/regional treatment, systemic treatment and supportive care) and indirect factors (modifiable and non-modifiable risk factors) that may have adverse effects on treatment-related haematological, cardiovascular, pulmonary and musculoskeletal components. Upper limb dysfunction and lymphoedema have been reported to be two of the most common side effects affecting the quality of life of breast cancer patients after breast cancer treatments. The elastic resistance band, which is widely used in strength training, has the advantage of being applied to various classes because it provides resistance angles in various postures and has a low risk of injury. However, few studies have been conducted on elastic resistance band application in patients with breast cancer. At the same time, evidence on the effectiveness of upper extremity aerobic exercise training in patients with breast cancer is limited. Therefore, this study aimed to investigate the effects of upper extremity aerobic exercise training combined with progressive resistance training and upper extremity aerobic exercise training alone on upper extremity exercise capacity, upper extremity functionality, sarcopenia, frailty, quality of life and lymphedema in patients with breast cancer.

Read the detailed description

According to updated data from the International Agency for Research on Cancer (IARC) for 2022, breast cancer in women is responsible for one in every four cancer cases and one in every six cancer deaths worldwide and is the second leading cause of global cancer incidence, accounting for 11.6% of all cancer cases, and the fourth leading cause of death from cancer worldwide, accounting for 6.9% of all cancer deaths. The prognosis of breast cancer has improved significantly with comprehensive screening programmes, early diagnosis and innovative systematic treatments, with a 5-year survival rate of 90% and a 10-year survival rate of approximately 80%. On the other hand, with increasing survival rates, various strategies are needed for the management of short- and long-term sequelae related to breast cancer treatments, especially considering quality of life. During or after breast cancer treatments, patients are exposed to various direct (local/regional treatment, systemic treatment and supportive care) and indirect factors (modifiable and non-modifiable risk factors) that may have adverse effects on haematological, cardiovascular, pulmonary and musculoskeletal components. Upper limb dysfunction and lymphoedema have been reported to be two of the most common side effects affecting the quality of life of breast cancer patients after breast cancer treatments. Up to 70% of breast cancer patients experience pain, discomfort and/or reduced physical function in the affected shoulder, arm and hand, depending on the type of surgery, rehabilitation programmes or assessment tools and other factors. The percentage of women experiencing lymphoedema after breast cancer surgery is very heterogeneous and varies between studies from 4% to over 60%. As a result of upper extremity dysfunction, decreased ability of individuals to perform activities of daily living is frequently observed. This is a major concern in terms of clinical and public health. In addition, the increase in arm volume and lymphoedema represent a significant threat to life. The American Cancer Society and the National Cancer Institute recommend exercise led by an expert as a safe and feasible method to reduce the risk of developing lymphoedema. Furthermore, many studies have observed that resistance training and concurrent training are beneficial in preventing short- and long-term upper extremity disorders. Resistance training and other forms of physical activity are among the most effective treatments to regain shoulder joint mobility, reduce pain and discomfort, and improve quality of life in breast cancer patients. In addition, some studies suggest that resistance exercise may reduce lymphoedema. However, there is still a lack of information for patients due to medical recommendations to restrict the affected arm and a lack of implementation of these recommendations in clinical practice, leading to greater fear of using the affected arm, lower physical activity, lower muscle strength and greater perceived weakness.

The elastic resistance band, which is widely used in strength training, has the advantage of being applied to various classes because it provides resistance angles in various postures and has a low risk of injury. However, few studies have been conducted on elastic resistance band application in patients with breast cancer. At the same time, evidence on the effectiveness of upper extremity aerobic exercise training in patients with breast cancer is limited. Therefore, this study aimed to investigate the effects of upper extremity aerobic exercise training combined with progressive resistance training and upper extremity aerobic exercise training alone on upper extremity exercise capacity, upper extremity functionality, sarcopenia, frailty, quality of life and lymphedema in patients with breast cancer.

03

Conditions studied

  • Breast Cancer
  • Upper Extremity
  • Resistance Exercise
  • Aerobic Exercise

Browse trials for

Keywords

  • breast cancer
  • Upper Extremity
  • resistance exercise training
  • Aerobic exercise training
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be between 18-80 years old,
  • Volunteering to participate in the research,
  • At least 15 months after breast cancer surgery,
  • No problems in reading and/or understanding the scales and being able to co-operate with the tests.
  • Physically inactive (60 minutes of structured exercise per week \<).

Exclusion criteria

Exclusion Criteria:

  • Presence of active infection,
  • Presence of bilateral breast cancer,
  • History of surgical, neurological or orthopaedic problems that may affect upper extremity functionality other than breast cancer surgery,
  • Having a neurological disease or other clinical diagnosis that may affect cognitive status,
  • Musculoskeletal and neurological disease that may affect exercise performance, symptomatic heart disease, previous lung surgery and malignant disease.
  • Presence of unstable hypertension or diabetes mellitus.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Upper Extremity Aerobic Exercise

    Participants will only receive a 12-week upper limb aerobic exercise training program.

    Other: Upper Extremity Aerobic Exercise Training

  • Experimental
    Upper Extremity Progressive Resistance Training Combined with Aerobic Exercise Training

    Participants will receive a 12-week upper extremity aerobic exercise training program plus upper extremity progressive resistance exercise training.

    Other: Upper Extremity Aerobic Exercise Training · Other: Upper Extremity Progressive Resistance Exercise Training

Interventions

  • OtherUpper Extremity Aerobic Exercise Training

    12 weeks of upper extremity aerobic exercise training, 3 sessions per week, 25 minutes per session.

  • OtherUpper Extremity Progressive Resistance Exercise Training

    Upper extremity progressive resistance training was gradually increased over 12 weeks using elastic resistance bands.

06

What researchers measure

Primary outcomes

  1. 6 minute Pegboard and Ring Test - 6PBRT

    Total number of rings inserted in six minutes

    Time frame: One Year

  2. Maximal Arm Exercise Capacity

    VO2peak requirement during arm ergometry will be estimated using MET levels calculated at each power output based on gender at various body weights and will be displayed in ml/kg/min (1 MET = 3.5 ml/kg/min)

    Time frame: One Year

Secondary outcomes

  1. Evaluation of Quality of Life

    European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) All scores were linearly transformed to a 0 to 100 scale. A high or healthy level of functioning is represented by a high functional score

    Time frame: One Year

  2. Peripheral Muscle Strength

    Hand grip strength by hand dynamometer

    Time frame: One Year

  3. Anthropometric Measurements

    Arm Circumference

    Time frame: One Year

  4. Comorbidity Assessment

    The Charlson Comorbidity Index According to this index developed by the Institute of Medicine, comorbid diseases are assessed according to their severity. is scored. Comorbidities are scored from mild disease state to severe disease state. are given a score of 1, 2, 3, 4, respectively, and the score obtained by summing the scores of comorbid diseases The severity of comorbidity is also calculated according to the weighted score. One point for every ten years over the age of forty (50-59: 1 point, 60-69: 2 points, etc.)

    Time frame: One Year

  5. Peripheral muscle strength assessment

    Peripheral muscle strength (knee extensors, shoulder abductors and hand grip strength) will be measured using a handheld digital dynamometer

    Time frame: One Year

  6. Evaluation of Upper Extremity Functionality

    Questionnaire Disability of Arm, Shoulder and Hand (Q-DASH) Each item is scored on a 5-point Likert scale (1-5).The maximum score is 100 points. Score increase shows an increase in disability.

    Time frame: One Year

  7. Assessment of Sarcopenia

    According to EWGSOP2, probable sarcopenia is defined by the first criterion and confirmed sarcopenia by the first and second criteria. Severe sarcopenia is considered if all three criteria are present.

    Time frame: One Year

  8. Assessment of Frailty Status

    Those who do not fulfil any of the criteria are defined as non-fragile group and those who fulfil 1 or 2 of the criteria are defined as pre-fragile group.

    Time frame: One Year

  9. Lymphoedema Evaluation

    Using circumference measurements starting from the wrist, the volume of the upper extremity was calculated by using an excel programme (Calculator: John Chambers) which calculates the volume by taking the sum of the volumes of truncated cones standing on top of each other. Lymphedema was considered positive in patients with a volume difference of more than 200 ml between the two arms.

    Time frame: One Year

07

Study locations

1 of 1 sites recruiting
  • Hcettepe University
    Ankara, State 06100, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Mar 2027, 19 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 19 months is below that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Nov 2026 → Mar 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2025
First posted
Jul 17, 2025
StartActual
Jul 8, 2025
Primary completionEst.
Mar 1, 2027was Nov 2026
CompletionEst.
Mar 1, 2027was Dec 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 1, 2026→Mar 1, 2027
Nov 17, 2026
Study completion
Dec 1, 2026→Mar 1, 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Nov 1, 2026→Mar 1, 2027
    Study completion Dec 1, 2026→Mar 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07070791
Responsible party
Ebru Calik (Professor, Hacettepe University) — Principal investigator
First posted
Jul 17, 2025
Start date
Jul 8, 2025
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Ebru Calik Kutukcu, PhD
Contact
ebru.calik@hacettepe.edu.tr
+903123051576 ext. 195
Naciye Vardar-Yagli, PhD
Contact
naciyevardar@yahoo.com
+03123051576 ext. 129
Melda Saglam, PhD
study chair · Hacettepe University
Ebru Calik Kutukcu, PhD
principal investigator · Hacettepe University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion